Last reviewed · How we verify
6-month clopidogrel therapy
At a glance
| Generic name | 6-month clopidogrel therapy |
|---|---|
| Also known as | Plavix |
| Sponsor | Seoul National University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of ZaStaprazan on Platelet Reactivity of Clopidogrel After PercuTaneous CoronAry InteRvention (PHASE4)
- STEMI Treated With a Polymer-free Sirolimus-coated Stent and P2Y12 Inhibitor-based SAPT Versus Conventional DAPT (NA)
- PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy (NA)
- Appropriate Duration of Anti-Platelet straTegy in Patients With Advance Chronic Kidney Disease After New Generation Drug Eluting Stents (ADAPT-CKD) (NA)
- Vascular Trial Associated Registry Pilot (PHASE4)
- Optimal Duration of Dual Antiplatelet Therapy After Stent-assisted Coiling (PHASE4)
- OCT-Guided Stent Optimization for Short-Duration Dual Antiplatelet Therapy in Stable Angina (NA)
- Ultrathin-strut Biodegradable Polymer Sirolimus-eluting Stents With P2Y12 Inhibitor-based Single Antiplatelet Therapy vs. Conventional DAPT for Unprotected Left Main Coronary Artery Disease (ULTIMATE-LM) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 6-month clopidogrel therapy CI brief — competitive landscape report
- 6-month clopidogrel therapy updates RSS · CI watch RSS
- Seoul National University Hospital portfolio CI